Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-02-21 DOI:10.1111/apt.70038

Annaswamy Raji, Ira Gantz, Michael Crutchlow, Heather Flynn, Lianzhe Xu, Anthony J. Rodgers, Radha Krishnan, Matthew L. Rizk, Shuai Hu, Keith D. Kaufman, Samuel S. Engel

引用次数: 0

Abstract

Fibroblast growth factor 21 (FGF21) is a metabolic regulator with demonstrated efficacy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). FGF21 signals through ‘c’ isoforms of the FGF receptors (FGFR) 1–3 and the co-receptor β-klotho.

Abstract Image

查看原文本刊更多论文

成纤维细胞生长因子 21（FGF21）是一种代谢调节因子，对治疗代谢功能障碍相关性脂肪性肝炎（MASH）有明显疗效。FGF21 通过 FGF 受体 (FGFR) 1-3 的'c'异构体和共受体 β-klotho 发出信号。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.